Figure 1.
Overview of Data and Analyses
(A) Publicly available genomic data for a large cohort of primary tumors were analyzed to identify clinically relevant features called cancer functional events.
(B) A panel of 1,001 genomically characterized human cancer cell lines.
(C) The catalog of CFEs from patient tumors was used to filter the set of molecular alterations identified in cell lines and subsequently was used for pharmacogenomic modeling.
(D) Cancer cell lines were screened for differential sensitivity against 265 anti-cancer compounds.
(E) The resultant datasets were used for pharmacogenomic modeling.